Results 201 to 210 of about 491,626 (323)

Spontaneous T-cell lymphoblastic lymphoma in a young ICR mouse: a case report. [PDF]

J Toxicol Pathol
Sung M, Choi JH, Sung SE, Kang KK, Park SH, Kim D, Lee S.   +6 more
europepmc   +1 more source

Extracorporeal Photopheresis for Chronic Graft‐Versus‐Host Disease According to 2014 NIH Consensus Criteria

Journal of Clinical Apheresis, Volume 40, Issue 6, December 2025.
ABSTRACT Chronic graft‐versus‐host disease (cGVHD) remains a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. Many cGVHD patients require prolonged systemic immunosuppression with corticosteroids, which carry significant adverse effects, and alternative therapies are often required.
Yitzhar Goretsky, Noa Holtzman, Sunwoo Han, Isildinha M. Reis, Vera Suzuki, Pepita Jean, Karla Mones, Meilin Diaz‐Paez, Cara Benjamin, Amer Beitinjaneh, Mark Goodman, Antonio Jimenez Jimenez, Lazaros Lekakis, Denise Pereira, Jay Spiegel, Yanyun Wu, Damian J. Green, Krishna V. Komanduri, Trent P. Wang   +18 more
wiley   +1 more source

Synchronous Occurrence of T-cell Lymphoblastic Lymphoma and High-Grade Glioma in a Pediatric Patient: A Case Report. [PDF]

Cureus
Thakur N, Bathla PS, Singh S, Bahl R, Varghese J.   +4 more
europepmc   +1 more source

Genomic characterization of pediatric B‐lymphoblastic lymphoma and B‐lymphoblastic leukemia using formalin‐fixed tissues

Pediatric Blood & Cancer, 2017
Julia A. Meyer, Delu Zhou, C. C. Mason, J. M. Downie, V. Rodic, M. Abromowitch, B. Wistinghausen, A. Termuhlen, A. Angiolillo, S. Perkins, M. Lones, P. Barnette, J. Schiffman, R. Miles   +13 more
semanticscholar   +1 more source

Four Pharmacogenomic Variants Strongly Linked to Corticosteroid‐Induced Avascular Necrosis in Children with Cancer

The Journal of Clinical Pharmacology, Volume 65, Issue 12, Page 1844-1854, December 2025.
Abstract Corticosteroids are effective anti‐cancer agents for treating hematologic malignancies in children. However, avascular necrosis (AVN) is a common and debilitating adverse effect, leading to bone death and impacting long‐term quality of life. This study aimed to uncover the genetic factors contributing to corticosteroid‐induced AVN in a well ...
Miguel Cordova‐Delgado, Erika N. Scott, Shahrad R. Rassekh, Catrina M. Loucks, Wan‐Chun Chang, Edward J. Raack, Jessica N. Trueman, Colin J. D. Ross, Bruce C. Carleton, the Canadian Pharmacogenomics Network for Drug Safety Consortium   +9 more
wiley   +1 more source

A case series of B-Lymphoblastic lymphoma with C-MYC rearrangement in children: diagnostic and therapeutic challenges. [PDF]

Ann Hematol
Yang X, Duan Y, Zhou C, Zhang N, Bai X, Jin L, Huang S, Zhang M.   +7 more
europepmc   +1 more source

Secondary Malignancies Following CAR T‐Cell Therapy for B‐Cell Malignancies: A Retrospective Analysis

eJHaem, Volume 6, Issue 6, December 2025.
ABSTRACT Introduction Chimeric antigen receptor T‐cell (CART) therapy has shown clinical efficacy in relapsed and refractory large B‐cell malignancies. There is emerging data on the long‐term complications including risk of secondary malignancies. We aimed to describe the incidence and characteristics of secondary malignancies following CART therapy ...
Joanne Britto, Audrey Y. H. Dong, Gregory Pond, Tobias Berg, Kylie Lepic, Tom Kouroukis, Gwynivere A. Davies, Graeme Fraser, Ronan Foley, Amaris K. Balitsky   +9 more
wiley   +1 more source

Association between medical comorbidities at diagnosis and paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma outcomes: protocol for a systematic review. [PDF]

BMJ Open
Amankwah EK, Mosha M, Dean J, Mayer J.
europepmc   +1 more source

Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma. [PDF]

Haematologica
Hughes AD, Pölönen P, Teachey DT.
europepmc   +1 more source

Donor‐Derived T‐Cell Redirection With Epcoritamab Achieving Complete Response After Early Post‐Allo‐HSCT Relapse of DLBCL

eJHaem, Volume 6, Issue 6, December 2025.
ABSTRACT Background Epcoritamab, a bispecific CD3×CD20 antibody, offers a promising treatment for relapsed diffuse large B‐cell lymphoma (DLBCL). Its efficacy and safety after allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remain unclear.
Yoshikazu Ikoma, Yuto Kaneda, Ryoma Shimazu, Daisuke Okamoto, Takuro Matsumoto, Nobuhiko Nakamura, Hiroshi Nakamura, Nobuhiro Kanemura, Hideko Goto, Naoki Katsumura, Masahito Shimizu   +10 more
wiley   +1 more source